iShares Global Healthcare ETF
$102.75−0.91 (−0.88%)
- Expense ratio
- 0.38%
- Fund size
- $4.3B
- 1Y return
- +19.9%
- Yield · Last 12 months
- 1.39%
- Holdings
- 109
- Volume · 30D
- 0.2M sh
- NAV per share
- $103.15
- 52W range
The ETF.net IXJ Grade
Score 68 of 100 sits in the B band. Bands: A ≥ 70, B ≥ 55, C ≥ 40, D ≥ 25, F < 25; the scale skips E.
Cost
What you pay to own it — the expense ratio plus trading frictions, ranked within its category.BScore 69Category rankMission
How faithfully it does the job it claims — tracking its mandate or index with minimal slippage.Not scoredRisk
How violently it can move — volatility, drawdown depth, and downside capture versus its category.BScore 69Category rankTradability
How cheaply and easily you can get in and out — liquidity, spread, and premium/discount stability.BScore 64Category rankHoldings
What it actually owns — the quality, breadth, and concentration of the underlying portfolio.BScore 68Category rankDurability
Whether it will still be here — the fund’s assets, age, flows, and issuer staying power.AScore 86Category rank
Our read on IXJ
BMost healthcare sector funds stop at the US border. IXJ tracks a global index instead: roughly 110 drugmakers, biotechs and device makers worldwide, and it has been doing it since 2001.
The fund seeks to track an index of global healthcare-sector equities, offering diversified access to pharmaceutical, biotech, and medical-device companies worldwide.
Why people hold it
- Global by charter. It tracks S&P's capped global health care index, so companies listed outside the US sit in the same basket as the American giants.ishares.com
- 0.38% a year, below the median fee in its broad healthcare peer group, for a portfolio of about 110 pharma, biotech and medical-device names.
- The word capped in the index name does real work: it limits how large any single mega-cap drugmaker can grow inside the fund.ishares.com
- Running since 2001 and now a multi-billion-dollar fund. That is a long operating record, not a launch-and-see product.
Worth knowing
- The worldwide reach carries a price tag: peers XLV and FHLC (0.08%) and VHT (0.09%) charge a fraction of IXJ's 0.38%.
- One sector, one storyline. Patent cliffs, trial data and drug-pricing politics tend to move the whole basket at once.
- Trading is moderate rather than heavy, so bid-ask spreads are worth a glance on larger orders.
IXJ Holdings
- Stocks
- 109
- 47%
- LLY
Sectors
- Health Care100.0%
Geography
- United States71.41%
- Switzerland9.80%
- United Kingdom5.21%
- Japan3.78%
- Denmark2.13%
- France1.78%
- Germany1.57%
- Ireland1.46%
- 2.85%
Developed 100% · Emerging 0%
IXJ Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
IXJ$11,991
Returns run to the Sep 22, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | IXJ |
|---|---|
| Year to date | +7.4% |
| 1 month | −3.0% |
| 3 months | +10.9% |
| 1 year | +19.9% |
| 3 years | +9.2% |
| 5 years | +5.2% |
| 10 years | +8.9% |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | IXJ |
|---|---|---|
| 2026 YTD | +7.4% | |
| 2025 | +15.0% | |
| 2024 | +0.6% | |
| 2023 | +3.6% | |
| 2022 | −4.9% | |
| 2021 | +19.6% | |
| 2020 | +12.7% |
IXJ in the news
IXJ Dividends
- 1.39%
- $1.44
- $0.85 per share
- Twice a year
Distribution history
| Ex-date | Pay date | Amount per share |
|---|---|---|
| Jun 15, 2026 | Jun 18, 2026 | $0.85 |
| Dec 16, 2025 | Dec 19, 2025 | $0.60 |
| Jun 16, 2025 | Jun 20, 2025 | $0.76 |
| Dec 17, 2024 | Dec 20, 2024 | $0.62 |
| Jun 11, 2024 | Jun 17, 2024 | $0.67 |
| Dec 20, 2023 | Dec 27, 2023 | $0.56 |
| Jun 7, 2023 | Jun 13, 2023 | $0.64 |
| Dec 13, 2022 | Dec 19, 2022 | $0.44 |
| Jun 9, 2022 | Jun 15, 2022 | $0.55 |
| Dec 13, 2021 | Dec 17, 2021 | $0.48 |
| Jun 10, 2021 | Jun 16, 2021 | $0.53 |
| Dec 14, 2020 | Dec 18, 2020 | $0.44 |
IXJ Risk
- 13.5%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 0.34
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −18.1%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 0.56
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
IXJ Cost
0.38%
IXJ0.38%
- The middle half of Health Care (Broad) funds
- Median 0.50%
9 of the 25 Health Care (Broad) funds charge less.